Storia in 2 fonti

Strides Pharma Science shares jump 9% after USFDA EIR for Bengaluru facility

Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru facility, concluding a recent cGMP inspection. The inspection ended with five observations, which the company addressed through corrective actions. The regulatory closure offers relief after the stocks recent weakness.

Raccontata da

economictimes.indiatimes.com

thehindu.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

economictimes.indiatimes.comStai leggendo2 g fa

Strides Pharma Science shares jump 9% after USFDA EIR for Bengaluru facility

FDA closed Strides' Bengaluru manufacturing facility inspection with EIR, resolving 5 Form 483 observations (May 2026). Regulatory clearance unlocks US market access and signals manufacturing compliance strength—critical indicators for managers evaluating outsourced pharma supply chain partnerships.

originale

thehindu.com1 g fa

USFDA clears Strides’ manufacturing unit in Bengaluru

Strides' Bengaluru manufacturing unit receives USFDA clearance, ensuring compliance for international pharmaceutical markets.

Leggi questa versione →

Timeline cronologica

giovedì 20 agosto 2026·economictimes.indiatimes.com
Strides Pharma Science shares jump 9% after USFDA EIR for Bengaluru facility
Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru facility, concluding a recent cGMP…
giovedì 20 agosto 2026·thehindu.com
USFDA clears Strides’ manufacturing unit in Bengaluru
Strides' Bengaluru manufacturing unit receives USFDA clearance, ensuring compliance for international pharmaceutical markets.